FDA Grants New Pancreatic Cancer Indication for Lynparza

The FDA granted a new indication to olaparib (Lynparza, AstraZeneca) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. 

Therapy should be selected based on an FDA-approved companion diagnostic for olaparib. 

The approval follows the Dec. 17 recommendation by the FDA Oncologic